Comment on ‘Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations’-Reference-Cited by-全球学者库

Comment on ‘Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations’

Published:2018-06-27 Issue:10 Volume:12 Page:1259-1259
ISSN:1873-9946
Container-title:Journal of Crohn's and Colitis
language:en
Short-container-title:

Author:

Yang Chen¹,Huang Xiaowen¹,Dai Shixue²³

Affiliation:

1. The First School of Clinical Medicine, Southern Medical University, Baiyun District, Guangzhou, Guangdong, China

2. Department of Gastroenterology, Guangdong General Hospital and Guangdong Academy of Medical Sciences, South China University of Technology, Guangzhou, Guangdong, China

3. Guangdong Geriatrics Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, South China University of Technology, Guangzhou, Guangdong, China

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

Link

http://academic.oup.com/ecco-jcc/article-pdf/12/10/1259/26469481/jjy096.pdf

Reference4 articles.

1. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease;Nyboe Andersen;JAMA,2014

2. Risk of lymphoma in patients with inflammatory bowel disease treated with anti-tumour necrosis factor alpha agents: a systematic review and meta-analysis;Yang;J Crohns Colitis,2018

3. Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn’s disease treated with infliximab [Remicade®] or conventional therapy;D’Haens;J Crohns Colitis,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming cancer risk in inflammatory bowel disease: new insights into preventive strategies and pathogenesis mechanisms including interactions of immune cells, cancer signaling pathways, and gut microbiota;Frontiers in Immunology;2024-01-15

2. Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review;Cancers;2023-07-27

3. Cancer in Inflammatory Bowel Disease;Gastroenterology Clinics of North America;2022-09

4. Risk of malignancy in patients with inflammatory bowel disease: A population‐based cohort study from China;International Journal of Cancer;2022-02-10

5. Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease;Journal of Drug Delivery Science and Technology;2021-08